Overview Financials News + Filings Key Docs Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
Apellis Pharmaceuticals, Inc. (APLS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
| 10/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/05/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/22/2023 |
8-K
| Other Events Interactive Data |
| 08/09/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 12,000 shares
@ $23.66, valued at
$283.9k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
| 08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/31/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/18/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/18/2023 |
4
| Machiels Alec (Director) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 1,250 shares
@ $64.79, valued at
$81k
Exercised 1,250 options to buy
@ $2.67, valued at
$3.3k
|
|
| 07/17/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 07/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in Apellis Pharmaceuticals Inc |
| 07/06/2023 |
4
| Watson David O. (General Counsel) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 8,510 shares
@ $89.98, valued at
$765.7k
|
|
| 07/06/2023 |
4
| Sullivan Timothy Eugene (CFO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 3,192 shares
@ $89.4109, valued at
$285.4k
Sold 3,287 shares
@ $90.4165, valued at
$297.2k
Sold 300 shares
@ $91.0983, valued at
$27.3k
Exercised 6,779 options to buy
@ $10.03, valued at
$68k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/29/2023 |
4
| Watson David O. (General Counsel) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Gifted 12,750 shares
@ $0
Gifted 12,750 shares
@ $0 |
|
| 06/09/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 12,000 shares
@ $91.35, valued at
$1.1M
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
| 06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/06/2023 |
4
| Sullivan Timothy Eugene (CFO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 1,600 shares
@ $90.6044, valued at
$145k
Sold 30,609 shares
@ $87.7886, valued at
$2.7M
Sold 7,064 shares
@ $88.3649, valued at
$624.2k
Sold 30,506 shares
@ $89.8259, valued at
$2.7M
Exercised 69,779 options to buy
@ $10.03, valued at
$699.9k
|
|
| 06/02/2023 |
4
| Lewis Karen (Chief People Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 5,000 shares
@ $86, valued at
$430k
Exercised 5,000 options to buy
@ $34.11, valued at
$170.6k
|
|
| 06/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/25/2023 |
4
| Francois Cedric (CEO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Gifted 20,000 shares
@ $0
Gifted 20,000 shares
@ $0 |
|
| 05/18/2023 |
4
| Machiels Alec (Director) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 1,250 shares
@ $88.66, valued at
$110.8k
Exercised 1,250 options to buy
@ $2.67, valued at
$3.3k
|
|
| 05/18/2023 |
4
| Francois Cedric (CEO) has filed a Form 4 on Apellis Pharmaceuticals, Inc.|
Txns:
| Sold 934 shares
@ $83.1711, valued at
$77.7k
Sold 1,800 shares
@ $83.845, valued at
$150.9k
Sold 14,611 shares
@ $85.0089, valued at
$1.2M
Sold 3,007 shares
@ $85.9012, valued at
$258.3k
Sold 7,528 shares
@ $87.0163, valued at
$655.1k
Sold 2,120 shares
@ $87.6739, valued at
$185.9k
Exercised 30,000 options to buy
@ $2.67, valued at
$80.1k
Exercised 20,000 options to buy
@ $2.67, valued at
$53.4k
|
|
| 05/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
|
|
|